This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical



Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact



Chronic immune thrombocytopenic purpura (cITP)cITP is an acquired autoimmune disorder that causes excessive bruising and bleeding resulting from unusually low levels of platelets. cITP is among the most common bleeding disorders and is nearly three times more prevalent than hemophilia. cITP is associated with significant morbidity and mortality and is often highly problematic for patients—complicating employability, insurability, and overall quality of life (QoL). Children may develop cITP after a viral infection and usually recover fully without treatment. In adults, however, the disorder is often long-term.1,2Materials

View materials for you and your patients


Find videos and on-demand webinars

  1. Ansteatt KT, Unzicker CJ, Hurn ML, et al. The need for comprehensive care for persons with chronic immune thrombocytopenic purpura. J Blood Med. 2020;11:457-463. doi: 10.2147/JBM.S289390. Accessed June 16, 2022.
  2. Immune thrombocytopenia (ITP). Mayo Clinic. Accessed June 16, 2022.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

You are now leaving Pfizer  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.